Employing the CAPP-seq (CAncer Personalized Profiling by deep Sequencing) pull-down approach, Newman and colleagues were able to detect, among other mutations, the EML4-ALK fusion in a cohort of advanced NSCLC patients [30]. This evidence concerns the gene ALK and non-small cell lung carcinoma.